Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Use of PRP technology in conservative treatment of diffuse lamellar keratitis after LASIK

Poster Details

First Author: V.Kurenkov RUSSIA

Co Author(s):    N. Kuznetsova   K. Chinenova   N. Kurenkova   S. Abramov   S. Kurenkova        

Abstract Details

Purpose:

Analysis of efficiency of PRP technology used for conservative treatment of diffuse lamellar keratitis after Lasik.

Setting:

LLC “Dr. Kurenkov Clinic”, Moscow, Russia

Methods:

Diffuse lamellar keratitis (DLK) is an extremely rare complication of Lasik. Clinical course duration and clinical presentation intensity are variable but in any case DLK requires a serious treatment.Two group of patients with DLK were formed. The first group (4 eyes) included patients subjected to conventional conservative treatment including local and systemic application of steroids. The second group (4 eyes) included patients which were administered PRP in the form of subconjunctival injections. Visual acuity, biomicroscopic presentation at the 1st, 2nd, 3rd, 4th, 5th, 7th, 10th and 14th day were evaluated in the course of treatment.

Results:

Starting from the second day after initiation of treatment the biomicroscopic presentation in the second group was always considerably better than in the first group. Visual acuity in the second group at the second day was higher by 0.2. By the third and fourth day, visual acuity in the second group was higher by 0.35 on the average. By the fifth day, visual acuity in the second group was higher by 0.3, by 0.22 at the seventh day, by 0.2 at the 10th day, and by 0.05 at the 14th day.

Conclusions:

Application of PRP technology in conservative treatment of DLK allows to obtain higher functional results in short terms. Further investigation of PRP in DLK treatment is perspective and requires a deeper analysis.

Financial Disclosure:

NONE

Back to Poster listing